Antengene licenses ATG-106 to K2 Therapeutics
June 22, 2026 | 11:40
Antengene entered an exclusive license agreement with K2 Therapeutics for ATG-106 and granted an option for an undisclosed bispecific TCE asset.
Mobile Version